Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Accumulated Expenses (2016 - 2019)

Neurocrine Biosciences' Accumulated Expenses history spans 10 years, with the latest figure at $38.9 million for Q4 2019.

  • For Q4 2019, Accumulated Expenses rose 42.43% year-over-year to $38.9 million; the TTM value through Dec 2019 reached $38.9 million, up 42.43%, while the annual FY2019 figure was $38.9 million, 42.43% up from the prior year.
  • Accumulated Expenses reached $38.9 million in Q4 2019 per NBIX's latest filing, up from $27.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $38.9 million in Q4 2019 to a low of $7.4 million in Q4 2015.
  • Average Accumulated Expenses over 5 years is $18.5 million, with a median of $17.8 million recorded in 2016.
  • The largest YoY upside for Accumulated Expenses was 160.5% in 2017 against a maximum downside of 7.46% in 2017.
  • A 5-year view of Accumulated Expenses shows it stood at $7.4 million in 2015, then grew by 29.91% to $9.6 million in 2016, then surged by 160.5% to $24.9 million in 2017, then increased by 9.8% to $27.3 million in 2018, then soared by 42.43% to $38.9 million in 2019.
  • Per Business Quant, the three most recent readings for NBIX's Accumulated Expenses are $38.9 million (Q4 2019), $27.3 million (Q4 2018), and $24.9 million (Q4 2017).